FORTIS-M: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-Small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens.

Trial Profile

FORTIS-M: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Oral Talactoferrin in Addition to Best Supportive Care in Patients With Non-Small Cell Lung Cancer Who Have Failed Two or More Prior Treatment Regimens.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Talactoferrin alfa (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms FORTIS-M
  • Sponsors Agenix
  • Most Recent Events

    • 02 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
    • 13 Aug 2012 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov
    • 13 Aug 2012 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top